Diabetes and COVID-19 risk: an miRNA perspective.,American Journal of Physiology-Heart and Circulatory Physiology

当前位置： X-MOL 学术 › J. Appl. Physiol. Heart Circulat. Physiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Diabetes and COVID-19 risk: an miRNA perspective.
American Journal of Physiology-Heart and Circulatory Physiology ( IF 4.1 ) Pub Date : 2020-08-07 , DOI: 10.1152/ajpheart.00489.2020
Paras K Mishra ₁ , Ritesh Tandon ₂ , Siddappa N Byrareddy ₃

Affiliation

COVID-19 and Diabetes Outcomes (CORONADO) trial revealed that 10.6% of diabetes mellitus patients hospitalized for coronavirus disease 2019 (COVID-19) and die within 7 days. Several studies from New York, Italy, and China confirm that diabetic patients are at a much high risk for mortality due to COVID-19. Besides respiratory illness, COVID-19 increases cardiac injury, and diabetic ketoacidosis. In the absence of specific guidelines for the prevention and treatment of COVID-19 for diabetic patients, they remain at higher risk and are more susceptible to COVID-19. Further, there is a scarcity of basic knowledge on how diabetes affects pathogenesis of severe acute respiratory coronavirus (SARS-CoV-2) infection. In diabetic patients, impaired glucose utilization alters metabolic and consequently biological processes instigating pathological remodeling, which has detrimental effects on cardiovascular systems. Majority of biological processes are regulated by non-coding microRNAs (miRNAs), which have emerged as a promising therapeutic candidate for several diseases. Considering the higher risk of mortality in diabetic COVID-19 patients, novel diagnostic test and treatment strategy are urgently warranted in post-COVID-19 era. Here, we describe potential roles of miRNA as a biomarker and therapeutic candidate, especially for heart failure, in diabetic COVID-19 patients.

更新日期：2020-08-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11